Company news
Lucid Diagnostics Inc. (NASDAQ:LUCD) news
Every Lucid Diagnostics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 13, 2026
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
August 5, 2026
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
July 30, 2026
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
May 14, 2026
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
April 30, 2026
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
April 24, 2026
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
April 23, 2026
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
April 9, 2026
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
April 2, 2026
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 30, 2026
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 26, 2026
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
March 12, 2026
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
February 4, 2026
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
January 21, 2026
PAVmed Announces Reverse Stock Split
December 30, 2025
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
December 9, 2025
Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
November 20, 2025
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
November 13, 2025
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
November 13, 2025
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 12, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
October 29, 2025
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
October 15, 2025
Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
September 25, 2025
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
September 16, 2025
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
September 11, 2025
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
September 10, 2025
Lucid Diagnostics Announces Proposed Public Offering of Common Stock
September 9, 2025
Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
September 5, 2025
Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
August 27, 2025
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
August 26, 2025
PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
August 14, 2025
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
Lucid Diagnostics to Participate in Upcoming Investor Conferences
August 5, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
July 30, 2025
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
July 16, 2025
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal ...
June 18, 2025
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
May 27, 2025
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
May 15, 2025
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
May 14, 2025
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
May 1, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
April 30, 2025
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
April 24, 2025
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
April 3, 2025
Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection ...
March 27, 2025
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 25, 2025
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 24, 2025
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
March 20, 2025
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
March 18, 2025
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
March 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
March 10, 2025